Daniel Serrano is the Director of Psychometrics at Pharmerit. Daniel has been working in psychometric applications to public health, clinical trials, and Patient-Centered Outcomes (PROs) for over 12 years.
Daniel co-designed and was primary statistician/psychometrician for two of the largest national prospective studies of migraine (American Migraine Prevalence and Prevention [AMPP] and the Chronic Migraine Epidemiology and Outcomes [CaMEO] studies). Daniel has worked on a large number of NIH and Industry funded studies in areas ranging from substance abuse, movement disorders, infectious disease, dementia, gynecologic disorders, neurodegenerative disorders, and rare diseases. His primary applied emphasis is within neurology. Daniel is concurrently clinical assistant professor in the Saul R. Korey Department of Neurology at the Albert Einstein College of Medicine. Daniel is a two-time winner of the Enrico Greppi award, and the Howard G. Wolff award. Daniel has supported FDA submissions at multiple Type-C meetings. Daniel specializes in linear and generalized linear models along with their mixed-effect extensions, longitudinal psychometric models, integrative data analysis, and the application of these techniques to randomized clinical trials. Daniel is a regular presenter at the International Meeting of the Psychometric Society, and has been an invited discussant at the Duke-Margolis Health Policy Institute/FDA working groups. Daniel received his PhD and MA in Psychometrics from the University of North Carolina.